Ausgabe 3/2024
Inhalt (17 Artikel)
- Open Access
- review
15 years Ludwig Boltzmann Institute for Hematology and Oncology (LBI HO): achievements and future perspectives
Peter Valent, Emir Hadzijusufovic, Irina Sadovnik, Thomas W. Grunt, Barbara Peter, Michael Willmann, Harald Herrmann, Daniel Ivanov, Gregor Eisenwort, Heidrun Karlic, Georg Greiner, Karoline V. Gleixner, Thomas Rülicke, Maik Dahlhoff, Philipp Staber, Wolfgang R. Sperr, Michael Pfeilstöcker, Thomas Lion, Felix Keil, Gregor Hoermann
- short review
Advanced stage Hodgkinʼs lymphoma 2024—Update on first line treatment
Barbara Lehner, Michael Panny
- short review
American Society of Hematology (ASH) update 2023—chronic lymphocytic leukemia
Thomas Nösslinger
- Open Access
- short review
Liquid profiling for patients with advanced cancer is ready for clinical integration
Samantha O. Hasenleithner, Ellen Heitzer
- Open Access
- short review
The molecular tumor board—a key element of precision oncology
Laura Boos, Andreas Wicki
- Open Access
- short review
Antibody–drug conjugates (ADCs) in lung cancer treatment
Romana E. Wass, David Lang, Andreas Horner, Bernd Lamprecht
- Open Access
- Short Review
Emerging drugs in breast cancer: a focus on antibody–drug conjugates and novel treatment options in luminal disease
Rupert Bartsch
- Open Access
- short review
Emerging treatment strategies in chronic B-cell malignancies—News from ICML 2023
Jan-Paul Bohn
- Open Access
- short review
Importance of allogeneic stem cell transplantation in myelofibrosis
Klaus Hirschbühl, Christoph Schmid
- original report
β-adrenergic modulation of IL-6/gp130 and SOCS-1 in multiple myeloma: therapeutic strategy for stress induced-inflammatory response
Raika Naiebi, Saeid Abroun, Amir Atashi, Leila Shafiee, Mohammadarian Akbari, Mohammad Hasan Maleki, Morvarid Siri
- Open Access
- case report
Seminal vesicle metastasis from transverse colon adenocarcinoma: a unique case report
Juliana Arenas Hoyos, Julian Serrano Giraldo, Andres Felipe Gutierrez Rojas